Center for Scientific Review; Notice of Closed Meetings, 49215-49216 [2017-22966]

Download as PDF Federal Register / Vol. 82, No. 204 / Tuesday, October 24, 2017 / Notices 49215 TABLE 1—Continued Application No. ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA ANDA 085720 085721 085778 086096 086189 086598 086795 087183 087296 087521 087772 087979 088030 089042 ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ ........ Drug Meprobamate Tablets USP, 200 mg ........................................................ Meprobamate Tablets USP, 400 mg ........................................................ Hydroxyzine HCl Injection USP, 25 mg/mL .............................................. Chlorpheniramine Maleate Injection USP, 10 mg/mL ............................... Ergoloid Mesylates Sublingual Tablets USP, 0.5 mg ............................... Nandrolone Decanoate Injection USP, 100 mg/mL .................................. Chlorothiazide Tablets USP, 250 mg ........................................................ Ergoloid Mesylates Sublingual Tablets USP, 1 mg .................................. Chlorthalidone Tablets USP, 25 mg ......................................................... Chlorthalidone Tablets USP, 50 mg ......................................................... Prednisone Tablets USP, 50 mg .............................................................. Chloroquine Phosphate Tablets USP, EQ 150 mg base ......................... Chloroquine Phosphate Tablets USP, EQ 300 mg base ......................... Procainamide HCl Extended-Release Tablets USP, 750 mg ................... Therefore, approval of the applications listed in table 1, and all amendments and supplements thereto, is hereby withdrawn as of November 24, 2017. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in table 1 that are in inventory on the date that this notice becomes effective (see the DATES section) may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first. Dated: October 18, 2017. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2017–23046 Filed 10–23–17; 8:45 am] BILLING CODE 4164–01–P BILLING CODE 4140–01–P asabaliauskas on DSKBBXCHB2PROD with NOTICES National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which Jkt 244001 Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44). Date: November 17, 2017. Time: 1:00 p.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Vasundhara Varthakavi, Ph.D., DVM, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, Room 3E70, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5020, varthakaviv@niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) [FR Doc. 2017–22967 Filed 10–23–17; 8:45 am] National Institutes of Health 17:47 Oct 23, 2017 would constitute a clearly unwarranted invasion of personal privacy. Dated: October 18, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. DEPARTMENT OF HEALTH AND HUMAN SERVICES VerDate Sep<11>2014 Applicant DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Center for Scientific Review; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. Do. confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Center for Scientific Review Special Emphasis Panel; International Research Ethics Training. Date: November 16, 2017. Time: 8:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Karin F. Helmers, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 20892, (301) 254– 9975, helmersk@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; PAR16–121 Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01). Date: November 16, 2017. Time: 12:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Raul Rojas, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 451–6319, rojasr@ mail.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Macromolecular Structure and Function. Date: November 20, 2017. Time: 1:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: C-L Albert Wang, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of E:\FR\FM\24OCN1.SGM 24OCN1 49216 Federal Register / Vol. 82, No. 204 / Tuesday, October 24, 2017 / Notices Health, 6701 Rockledge Drive, Room 4146, MSC 7806, Bethesda, MD 20892, 301–435– 1016, wangca@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: October 18, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–22966 Filed 10–23–17; 8:45 am] BILLING CODE 4140–01–P ADVISORY COUNCIL ON HISTORIC PRESERVATION Notice of Advisory Council on Historic Preservation Quarterly Business Meeting Advisory Council on Historic Preservation. ACTION: Notice of Advisory Council on Historic Preservation Quarterly Business Meeting. AGENCY: Notice is hereby given that the Advisory Council on Historic Preservation (ACHP) will hold its next quarterly meeting on Thursday, November 9 2017. The meeting will be held in Room SR325 at the Russell Senate Office Building at Constitution and Delaware Avenues NE., Washington, DC, starting at 8:30 a.m. DATES: The quarterly meeting will take place on Thursday, November 9 2017, starting at 8:30 a.m. ADDRESSES: The meeting will be held in Room SR325 at the Russell Senate Office Building at Constitution and Delaware Avenues NE., Washington, DC. SUMMARY: asabaliauskas on DSKBBXCHB2PROD with NOTICES Cindy Bienvenue, 202–517–0202, cbienvenue@achp.gov. SUPPLEMENTARY INFORMATION: The Advisory Council on Historic Preservation (ACHP) is an independent federal agency that promotes the preservation, enhancement, and sustainable use of our nation’s diverse historic resources, and advises the President and the Congress on national historic preservation policy. The goal of the National Historic Preservation Act (NHPA), which established the ACHP in 1966, is to have federal agencies act as responsible stewards of our nation’s resources when their actions affect historic properties. The ACHP is the only entity with the legal responsibility to encourage federal agencies to factor historic preservation into their decision 17:47 Oct 23, 2017 Jkt 244001 Authority: 54 U.S.C. 304102. Dated: October 18, 2017. Javier E. Marques, General Counsel. [FR Doc. 2017–23000 Filed 10–23–17; 8:45 am] BILLING CODE 4310–K6–P FOR FURTHER INFORMATION CONTACT: VerDate Sep<11>2014 making. For more information on the ACHP, please visit our Web site at www.achp.gov. The agenda for the upcoming quarterly meeting of the ACHP is the following: I. Chairman’s Welcome II. Section 106 Issues A. Administration Infrastructure Initiatives B. ACHP Response to Recent Natural Disasters C. Proposed Exemption Regarding Railroad and Rail Transit Rights of Way D. ACHP Report to the President Pursuant to Executive Order 13287 E. Development of an Online Section 106 Forum F. ACHP Regulatory Review Progress III. Historic Preservation Policy and Programs A. Policy Statement on Commemorative Works B. ACHP Recommendations for the Future of the National Historic Preservation Program C. Historic Preservation Legislation in the 115th Congress D. ACHP Speakers’ Bureau Proposal E. ACHP/HUD Historic Preservation Award Follow Up IV. New Business V. Adjourn The meetings of the ACHP are open to the public. If you need special accommodations due to a disability, please contact Cindy Bienvenue, 202– 517–0202 or cbienvenue@achp.gov, at least seven (7) days prior to the meeting. DEPARTMENT OF HOMELAND SECURITY Coast Guard [Docket No. USCG–2017–0158] Collection of Information Under Review by Office of Management and Budget; OMB Control Number: 1625– 0017 Coast Guard, DHS. Thirty-day notice requesting comments. AGENCY: ACTION: In compliance with the Paperwork Reduction Act of 1995 the U.S. Coast Guard is forwarding an Information Collection Request (ICR), SUMMARY: PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 abstracted below, to the Office of Management and Budget (OMB), Office of Information and Regulatory Affairs (OIRA), requesting approval for reinstatement, without change, of the following collection of information: 1625–0017, Various International Agreement Safety Certificates and Documents. Our ICR describe the information we seek to collect from the public. Review and comments by OIRA ensure we only impose paperwork burdens commensurate with our performance of duties. DATES: Comments must reach the Coast Guard and OIRA on or before November 24, 2017. ADDRESSES: You may submit comments identified by Coast Guard docket number [USCG–2017–0158] to the Coast Guard using the Federal eRulemaking Portal at https://www.regulations.gov. Alternatively, you may submit comments to OIRA using one of the following means: (1) Email: dhsdeskofficer@ omb.eop.gov. (2) Mail: OIRA, 725 17th Street NW., Washington, DC 20503, attention Desk Officer for the Coast Guard. A copy of the ICR is available through the docket on the Internet at https:// www.regulations.gov. Additionally, copies are available from: Commandant (CG–612), ATTN: Paperwork Reduction Act Manager, U.S. Coast Guard, 2703 Martin Luther King Jr. Ave. SE., Stop 7710, Washington, DC 20593–7710. FOR FURTHER INFORMATION CONTACT: Contact Mr. Anthony Smith, Office of Information Management, telephone 202–475–3532, or fax 202–372–8405, for questions on these documents. SUPPLEMENTARY INFORMATION: Public Participation and Request for Comments This Notice relies on the authority of the Paperwork Reduction Act of 1995; 44 U.S.C. Chapter 35, as amended. An ICR is an application to OIRA seeking the approval, extension, or renewal of a Coast Guard collection of information (Collection). The ICR contains information describing the Collection’s purpose, the Collection’s likely burden on the affected public, an explanation of the necessity of the Collection, and other important information describing the Collection. There is one ICR for each Collection. The Coast Guard invites comments on whether this ICR should be granted based on the Collection being necessary for the proper performance of Departmental functions. In particular, the Coast Guard would appreciate comments addressing: (1) The practical utility of the Collection, (2) the accuracy E:\FR\FM\24OCN1.SGM 24OCN1

Agencies

[Federal Register Volume 82, Number 204 (Tuesday, October 24, 2017)]
[Notices]
[Pages 49215-49216]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-22966]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; International Research Ethics Training.
    Date: November 16, 2017.
    Time: 8:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892.
    Contact Person: Karin F. Helmers, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 3148, MSC 7770, Bethesda, MD 
20892, (301) 254-9975, [email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; PAR16-121 Early-Stage Preclinical Validation of Therapeutic 
Leads for Diseases of Interest to the NIDDK (R01).
    Date: November 16, 2017.
    Time: 12:00 p.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Raul Rojas, Ph.D., Scientific Review Officer, 
Center for Scientific Review, National Institutes of Health, 6701 
Rockledge Drive, Room 6185, Bethesda, MD 20892, (301) 451-6319, 
[email protected].

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Macromolecular Structure and Function.
    Date: November 20, 2017.
    Time: 1:00 p.m. to 6:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Telephone Conference Call).
    Contact Person: C-L Albert Wang, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of

[[Page 49216]]

Health, 6701 Rockledge Drive, Room 4146, MSC 7806, Bethesda, MD 
20892, 301-435-1016, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: October 18, 2017.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-22966 Filed 10-23-17; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.